TEVA PHARMACEUTICAL INDUSTRIES LTD
About TEVA PHARMACEUTICAL INDUSTRIES LTD
Teva Pharmaceutical, based in Israel, is the world's leading generic drug manufacturer. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in two main therapeutic areas: neurology and immunology. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $17.3B
- Net income
- $1.4B
- Total assets
- $40.7B
- Market cap
- $39.8B
- Gross margin
- 51.8%
- Operating margin
- 12.5%
- Net margin
- 8.2%
Source: SEC EDGAR · updated Jun 8, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $17.3B
- Cost of revenue
- $8.3B
- Gross profit
- $8.9B
- Operating expenses
- $6.8B
- Operating income
- $2.2B
- Income tax
- -$180.0M
- Net income
- $1.4B
- EPS (basic)
- $1.23
- EPS (diluted)
- $1.21
Balance sheet
- Total assets
- $40.7B
- Current assets
- $13.9B
- Total liabilities
- $32.8B
- Current liabilities
- $13.5B
- Shareholders’ equity
- $7.9B
Cash flow
- Operating cash flow
- $1.6B
- Investing cash flow
- $737.0M
- Financing cash flow
- -$2.2B
- Net cash flow
- $256.0M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $39.8B
- P/E ratio
- 27.8
- EPS (diluted)
- $1.21
- Dividend yield
- 1.01%
- Shares outstanding
- 1.2B
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Feb 16, 1982
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Profitable — net income of $1.4B in FY2025.
- Revenue grew 9% from FY2021 to FY2025.
- Gross margin of 51.8%, net margin 8.2%.
- Trading 8% below its 52-week high.
- Pays a dividend yielding about 1.01% annually.
- Valued at a price-to-earnings (P/E) ratio of 27.8.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review TEVA PHARMACEUTICAL INDUSTRIES LTD.
Write a review
News about TEVA PHARMACEUTICAL INDUSTRIES LTD
News & sentiment via Polygon.io
